NBIX News and Press, Neurocrine Biosciences Inc. From 09/10/22

The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down more than 19%, even though both have rallied a bit in the past few months. Contrast that with Vertex Pharmaceuticals (N...

Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference PR Newswire SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20 th Annual Global H...

Summary Today, we are revisiting Xenon Pharmaceuticals for the first time in 2022. The company is well-funded and advancing several compounds in its pipeline, one of which might have blockbuster potential. An investment analysis follows in the paragraphs below. "...

Summary Neurocrine is acquiring beaten-down Diurnal Group for $57M, primarily to accelerate its ex-U.S. business development. Diurnal has a pipeline of hormone-based therapeutics, including Efmody (commercialized in Europe), but the pipeline is likely secondary to the clinical/com...

The shares of U.K.-based biotech Diurnal rose in London in the morning hours Tuesday after the company announced a deal to be acquired by San Diego, California-based Neurocrine Biosciences ( NASDAQ: NBIX ) for nearly $57M in cash. Per the terms, neurology-focused NBIX will...

Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%. Management announced that '104 failed to show meaningful efficacy in a Phase II proof-of-concept study, and the company has few near-term clinical catalysts. ...

Improving VBR pick performance since late July is discussed. 5 new buy signals are highlighted. A super-bullish technical and fundamental setup for Canadian Solar is analyzed in more detail. During the last few weeks, I have been able to find some decent winners for Seek...

Neurocrine Biosciences ( NASDAQ: NBIX ) stock rose ~8% on Aug. 5 after the company's Q2 revenue beat estimates. Total revenues grew 31% Y/Y to $378.2M, while product sales increased 32% Y/Y to $352M. Tardive dyskinesia (TD) therapy Ingrezza sales amounted t...

Sosei Group ( OTCPK:SOLTF ) is getting $30M as a milestone payment from Neurocrine Biosciences ( NASDAQ: NBIX ) as NBI-1117568 was cleared by the U.S. Food and Drug Administration (FDA) for a phase 2 trial to treat schizophrenia. Neurocrine's investigatio...

Image source: The Motley Fool. Neurocrine Biosciences (NASDAQ: NBIX) Q2 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript